4/21/2021 8:15:02 AM
Summit Therapeutics Commences Previously-announced Rights Offering Of Up To 14.3 Mln Shares
3/17/2021 7:07:41 AM
Summit Therapeutics Q4 Loss Per Share $0.18 Vs Loss $0.34 Last Year
11/23/2020 7:11:37 AM
Summit Therapeutics Appoints Mahkam Zanganeh As COO
6/8/2020 7:31:18 AM
Summit Therapeutics Appoints Michael Donaldson As CFO
3/30/2016 9:56:48 AM
Canaccord Reiterates Summit Therapeutics plc (SMMT) At Buy With $14 Price Target
2/1/2016 10:05:51 AM
Canaccord Starts Summit Therapeutics plc (SMMT) At Buy With $14 Price Target